However, efforts to evaluate the therapeutic benefit in targeting hGIIA enzyme activity with a potent but non-selective sPLA2 inhibitor in Phase III clinical trials in patients with acute coronary syndrome have been unsuccessful due to a lack of efficacy and increased risk of serious adverse cardiac events [85], indicating the need for selective hGIIA inhibitors and a greater understanding of the functional role of sPLA2 enzymes in the development of coronary artery disease. The gene discussed is PLA2G2A; the disease is acute coronary syndrome.